News Focus
News Focus
Followers 55
Posts 4229
Boards Moderated 0
Alias Born 03/20/2014

Re: None

Thursday, 06/20/2024 8:07:24 PM

Thursday, June 20, 2024 8:07:24 PM

Post# of 517552
Filed under outside chance;

Dr. Missling said he would file for NDA after adult Rett trail met endpoints. Then it seemed he was waiting for Excellence which made sense.

Excellence had an issue with 1 or 2 in the placebo group showing improvement, throwing off the Stats, so step back and regroup. However there was a large effect and it was a very positive result despite the lack of statistical significance.

Now the focus is all on AD and that is looking very good. Yes, another Rett trial is being planned but the most important aspect of Excellence was confirmed with the safety of Blarcamesine in children and stat sig was missed by a hair.

I believe there is a case for approval for Rett, with the next trial moving into a P-4 as confirmatory.

That would qualify as a surprise, which has been promised.

It would at least open the door for off label but not sure how the money metrics would make that attractive.

All my posts are my opinion only and shouldn’t be used for decisions regarding purchasing or selling.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News